Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion-Reference-Cited by-同舟云学术

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion

Published:2018-09-26 Issue:12 Volume:8 Page:1529-1539
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Piotrowska Zofia,Isozaki Hideko,Lennerz Jochen K.,Gainor Justin F.,Lennes Inga T.,Zhu Viola W.,Marcoux Nicolas^ORCID,Banwait Mandeep K.,Digumarthy Subba R.,Su Wenjia,Yoda Satoshi^ORCID,Riley Amanda K.,Nangia Varuna,Lin Jessica J.^ORCID,Nagy Rebecca J.,Lanman Richard B.^ORCID,Dias-Santagata Dora,Mino-Kenudson Mari,Iafrate A. John,Heist Rebecca S.,Shaw Alice T.,Evans Erica K.,Clifford Corinne,Ou Sai-Hong I.,Wolf Beni,Hata Aaron N.,Sequist Lecia V.^ORCID

Funder

HHS | NIH | National Cancer Institute (NCI)

American Cancer Society (ACS)

LUNGevity Foundation

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 325 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Xie-Bai-San increases NSCLC cells sensitivity to gefitinib by inhibiting Beclin-1 mediated autophagosome formation;Phytomedicine;2024-03

2. Structure-based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Metabolic Reactivity Studies of Quinazoline Derivatives for their Anti-EGFR Activity Against Tumor Angiogenesis;Current Medicinal Chemistry;2024-02

3. Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers;2024-01-17

4. Epidermal growth factor receptor–mutated non–small cell lung cancer: a clinical approach;Lung Cancer;2024

5. EML4-ALK Variant 3a/b as a mechanism of osimertinib resistance in a patient with EGFR L858R positive NSCLC;Cancer Genetics;2024-01